Literature DB >> 22365524

Sarcomas and the immune system: implications for therapeutic strategies.

Valerie Francescutti1, Joseph J Skitzki.   

Abstract

Soft-tissue sarcomas are a heterogeneous group of tumors that are capable of generating host immune responses. Historically the role of antitumor immunity was first studied in soft-tissue sarcomas. Subsequent in vitro studies, preclinical models, and clinical observations have provided ample evidence for an immunologic approach to sarcoma treatment. Initial clinical trials involving vaccines and adoptive immunotherapy have demonstrated promising results. The continued search for sarcoma tumor-associated antigens as specific targets is central to the clinical translation of effective immunotherapies. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22365524     DOI: 10.1016/j.soc.2011.11.002

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  4 in total

Review 1.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

2.  Pyroptosis-Related Gene Signature Is a Novel Prognostic Biomarker for Sarcoma Patients.

Authors:  Dalong Wei; Xiaoling Lan; Zhiqun Huang; Qiang Tang; Zechen Wang; Yanfei Ma; Liuzhi Wei; Qiuju Wei; Jingjie Zhao; Jiajia Shen; Siyuan He; Jian Song; Lingzhang Meng; Qianli Tang
Journal:  Dis Markers       Date:  2021-12-03       Impact factor: 3.434

3.  Identification of Ferroptosis-Related Genes as Biomarkers for Sarcoma.

Authors:  Zhiyuan Guan; Shengfu Liu; Liying Luo; Zhong Wu; Shan Lu; Zhiqiang Guan; Kun Tao
Journal:  Front Cell Dev Biol       Date:  2022-03-01

4.  Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report.

Authors:  Kananathan Ratnavelu; Baskar Subramani; Chithra Ramanathan Pullai; Kohila Krishnan; Sheela Devi Sugadan; Manjunath Sadananda Rao; Abhi Veerakumarasivam; Xuewen Deng; Terunuma Hiroshi
Journal:  Oncol Lett       Date:  2013-03-12       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.